Rivaroxaban for Treatment in Venous or Arterial Thrombosis in Neonates

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

November 19, 2015

Primary Completion Date

December 18, 2017

Study Completion Date

December 18, 2017

Conditions
Thromboembolism
Interventions
DRUG

Rivaroxaban (Xarelto, BAY59-7939)

Body weight adjusted dosing of rivaroxaban to achieve a similar exposure in the range as that observed in adults treated for venous thromboembolism (VTE) with 20 mg once daily.

Trial Locations (9)

1090

Vienna

20122

Milan

28007

Madrid

28046

Madrid

34059

Montpellier

91052

Erlangen

5262000

Ramat Gan

08035

Barcelona

35-100

Izmir

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Janssen Research & Development, LLC

INDUSTRY

lead

Bayer

INDUSTRY